دورية أكاديمية

EFNB1 Acts as a Novel Prognosis Marker in Glioblastoma through Bioinformatics Methods and Experimental Validation

التفاصيل البيبلوغرافية
العنوان: EFNB1 Acts as a Novel Prognosis Marker in Glioblastoma through Bioinformatics Methods and Experimental Validation
المؤلفون: Yaohong Shi, Yuanyuan Sun, Hongyan Cheng, Chen Wang
المصدر: Journal of Oncology, Vol 2021 (2021)
بيانات النشر: Hindawi Limited
سنة النشر: 2021
المجموعة: Directory of Open Access Journals: DOAJ Articles
مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Purpose. Ephrin B1 (EFNB1), the Eph-associated receptor tyrosine kinase ligand, is suggested to have an important function in neurodevelopment. However, its contribution to glioblastoma multiforme (GBM) remains uncertain. This study aimed to determine the prognostic power and immune implication of EFNB1 in GBM. Methods. We first identified differentially coexpressed genes within GBM relative to noncarcinoma samples from GEO and TCGA databases by WGCNA. The STRING online database and the maximum cluster centrality (MCC) algorithm in Cytoscape software were used to design for predicting protein-protein interactions (PPI) and calculating pivot nodes, respectively. The expression of hub genes in cancer and noncancer tissues was verified by an online tool gene expression profile interactive analysis (GEPIA). Thereafter, the TISIDB online tool with Cox correlation regression method was employed to screen for immunomodulators associated with EFNB1 and to model the risk associated with immunomodulators. Results. Altogether 201 differentially expressed genes (DEGs) were discovered. After that, 10 hub genes (CALB2, EFNB1, ENO2, EPHB4, NES, OBSCN, RAB9B, RPL23A, STMN2, and THY1) were incorporated to construct the PPI network. As revealed by survival analysis, EFNB1 upregulation predicted poor overall survival (OS) for GBM cases. Furthermore, we developed a prognostic risk signature according to the EFNB1-associated immunomodulators. Kaplan–Meier survival analysis and receiver operating characteristic method were adopted for analysis, which revealed that our signature showed favorable accuracy of prognosis prediction. Finally, EFNB1 inhibition was found to block cell proliferation and migration in GBM cells. Conclusion. The above results indicate that EFNB1 participates in cancer immunity and progression, which is the candidate biomarker for GBM.
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1687-8469
العلاقة: http://dx.doi.org/10.1155/2021/4701680Test; https://doaj.org/toc/1687-8469Test; https://doaj.org/article/b9306f2e69474a2ead6cc1402b661412Test
DOI: 10.1155/2021/4701680
الإتاحة: https://doi.org/10.1155/2021/4701680Test
https://doaj.org/article/b9306f2e69474a2ead6cc1402b661412Test
رقم الانضمام: edsbas.8E5CFF9D
قاعدة البيانات: BASE
الوصف
تدمد:16878469
DOI:10.1155/2021/4701680